NASDAQ:IRMD
iRadimed Corporation Stock News
$42.03
-0.620 (-1.45%)
At Close: May 17, 2024
IRADIMED CORPORATION Announces Appointment of Hilda Scharen-Guivel to Board of Directors
08:05pm, Thursday, 06'th Oct 2022 GlobeNewswire Inc.
WINTER SPRINGS, Fla., Oct. 06, 2022 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) today announced the appointment of Hilda Scharen-Guivel to the Iradimed Board of Dire
Tesla, Autodesk And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
10:07am, Thursday, 25'th Aug 2022 Benzinga
Snowflake Inc. (NYSE: SNOW) surged 17.4% to $187.18 in pre-market trading after the company reported better-than-expected Q2 sales results and issued product revenue guidance.
FREYR Battery (NYSE: FRE
3 Healthcare Stocks With High Profit Margins
09:13am, Wednesday, 10'th Aug 2022 The Motley Fool
If you want to invest in profitable healthcare companies in this bear market, these all look like good bets.
3 Healthcare Stocks With High Profit Margins
05:13am, Wednesday, 10'th Aug 2022
If you want to invest in profitable healthcare companies in this bear market, these all look like good bets.
IRadimed (IRMD) Beats Q2 Earnings and Revenue Estimates
04:25pm, Friday, 29'th Jul 2022 Zacks Investment Research
iRadimed (IRMD) delivered earnings and revenue surprises of 12.50% and 0.65%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
IRADIMED CORPORATION Announces Second Quarter 2022 Financial Results
03:00pm, Friday, 29'th Jul 2022 GlobeNewswire Inc.
WINTER SPRINGS, Fla., July 29, 2022 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD), announced today its financial results for the three and six months ended June 30, 202
IRadimed Corporation (IRMD) CEO Roger Susi on Q2 2022 Results - Earnings Call Transcript
02:30pm, Friday, 29'th Jul 2022
IRadimed Corporation (NASDAQ:IRMD ) Q2 2022 Earnings Conference Call July 29, 2022 11:00 AM ET Company Participants Roger Susi – President and Chief Executive Officer Jack Glenn – Chief Financial
UPDATE - IRADIMED CORPORATION to Hold 2022 Second Quarter Financial Results Conference Call on July 29th
05:57pm, Thursday, 28'th Jul 2022 GlobeNewswire Inc.
WINTER SPRINGS, Fla., July 28, 2022 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2022 second quarter financial results before the market
UPDATE - IRADIMED CORPORATION to Hold 2022 Second Quarter Financial Results Conference Call on July 29th
01:57pm, Thursday, 28'th Jul 2022
WINTER SPRINGS, Fla., July 28, 2022 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2022 second quarter financial results before the market op
IRADIMED CORPORATION to Hold 2022 Second Quarter Financial Results Conference Call on July 29th
08:30pm, Friday, 22'nd Jul 2022 GlobeNewswire Inc.
WINTER SPRINGS, Fla., July 22, 2022 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2022 second quarter financial results before the market
IRADIMED CORPORATION to Hold 2022 Second Quarter Financial Results Conference Call on July 29th
04:30pm, Friday, 22'nd Jul 2022
WINTER SPRINGS, Fla., July 22, 2022 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2022 second quarter financial results before the market op
IRadimed: Reduce Equity Beta With Upside Capture
05:30pm, Monday, 18'th Jul 2022
IRadimed presents us with the alternative risk premia that investors are rewarding in FY22. Bottom-line fundamentals are strengthening whilst the stock has diverged away from the medtech sector.
IRADIMED Names John F. Glenn Chief Financial Officer
08:05pm, Thursday, 26'th May 2022 GlobeNewswire Inc.
WINTER SPRINGS, Fla., May 26, 2022 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD), today announced that John (Jack) Glenn has been appointed Chief Financial Officer effective on or before J
After Plunging 27.4% in 4 Weeks, Here's Why the Trend Might Reverse for iRadimed (IRMD)
01:35pm, Tuesday, 10'th May 2022 Zacks Investment Research
iRadimed (IRMD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising
After Plunging 27.4% in 4 Weeks, Here's Why the Trend Might Reverse for iRadimed (IRMD)
11:18am, Tuesday, 10'th May 2022
iRadimed (IRMD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising
